Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus SPRX 105.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus SPRX 105.
IMPOYZ vs SPRX-105
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
100 mg orally twice daily
SPRX-105 is administered orally at a dose of 50 mg once daily.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Category C
Category C
Unknown
Unknown